Clinical advances in antibody-drug conjugates for hematological malignancies
An antibody-drug conjugate (ADC) is a targeted therapeutic drug composed of a monoclonal antibody linked to a small-molecule cytotoxic drug via a linker. Once administered, ADCs bind to tumor-specific antigens, forming ADC-antigen complexes, which are internalized through endocytosis. The linkers ar...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Shanghai Jiao Tong University (Medical Science)
2024-12-01
|
| Series: | Shanghai Jiaotong Daxue xuebao. Yixue ban |
| Subjects: | |
| Online Access: | https://xuebao.shsmu.edu.cn/article/2024/1674-8115/1674-8115-2024-44-12-1607.shtml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555217937596416 |
|---|---|
| author | TANG Sijie MI Jianqing |
| author_facet | TANG Sijie MI Jianqing |
| author_sort | TANG Sijie |
| collection | DOAJ |
| description | An antibody-drug conjugate (ADC) is a targeted therapeutic drug composed of a monoclonal antibody linked to a small-molecule cytotoxic drug via a linker. Once administered, ADCs bind to tumor-specific antigens, forming ADC-antigen complexes, which are internalized through endocytosis. The linkers are then cleaved via endosomal-lysosome pathway and the cytotoxic drug is released, which induces apoptosis in the target cells. ADCs combine the advantages of monoclonal antibody drugs and cytotoxic drugs. They are able to reduce damage to normal cells while killing target cells, thus exhibiting higher anti-tumor efficiency. As the treatment of hematological malignancies gradually advances into the era of targeted immunotherapy, ADCs, as one of the hot spots, have shown broad prospects and also face many challenges in drug development and clinical application. Currently marketed ADCs in China include brentuximab vedotin (anti-CD30), inotuzumab ozogamicin (anti-CD22) and polatuzumab vedotin (anti-CD79B), while those marketed abroad include gemtuzumab ozogamicin (anti-CD33) and loncastuximab tesirine (anti-CD19), all demonstrating good efficacy and safety in clinical practice. Additionally, ADCs targeting different antigens such as CD123, CD19, CD20, receptor tyrosine kinase-like orphan receptor 1 (ROR1), and CD38 are undergoing clinical studies. Globally, there are over a hundred ADCs in development, and it is hoped that more breakthroughs will be achieved in the future to further optimize the treatment strategies for hematologic malignancies. |
| format | Article |
| id | doaj-art-176180852f2e4abcb02058621655de6e |
| institution | Kabale University |
| issn | 1674-8115 |
| language | zho |
| publishDate | 2024-12-01 |
| publisher | Editorial Office of Journal of Shanghai Jiao Tong University (Medical Science) |
| record_format | Article |
| series | Shanghai Jiaotong Daxue xuebao. Yixue ban |
| spelling | doaj-art-176180852f2e4abcb02058621655de6e2025-01-08T05:52:54ZzhoEditorial Office of Journal of Shanghai Jiao Tong University (Medical Science)Shanghai Jiaotong Daxue xuebao. Yixue ban1674-81152024-12-0144121607161410.3969/j.issn.1674-8115.2024.12.0151674-8115（2024）12-1607-08Clinical advances in antibody-drug conjugates for hematological malignanciesTANG Sijie0MI Jianqing1Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200025, ChinaDepartment of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200025, ChinaAn antibody-drug conjugate (ADC) is a targeted therapeutic drug composed of a monoclonal antibody linked to a small-molecule cytotoxic drug via a linker. Once administered, ADCs bind to tumor-specific antigens, forming ADC-antigen complexes, which are internalized through endocytosis. The linkers are then cleaved via endosomal-lysosome pathway and the cytotoxic drug is released, which induces apoptosis in the target cells. ADCs combine the advantages of monoclonal antibody drugs and cytotoxic drugs. They are able to reduce damage to normal cells while killing target cells, thus exhibiting higher anti-tumor efficiency. As the treatment of hematological malignancies gradually advances into the era of targeted immunotherapy, ADCs, as one of the hot spots, have shown broad prospects and also face many challenges in drug development and clinical application. Currently marketed ADCs in China include brentuximab vedotin (anti-CD30), inotuzumab ozogamicin (anti-CD22) and polatuzumab vedotin (anti-CD79B), while those marketed abroad include gemtuzumab ozogamicin (anti-CD33) and loncastuximab tesirine (anti-CD19), all demonstrating good efficacy and safety in clinical practice. Additionally, ADCs targeting different antigens such as CD123, CD19, CD20, receptor tyrosine kinase-like orphan receptor 1 (ROR1), and CD38 are undergoing clinical studies. Globally, there are over a hundred ADCs in development, and it is hoped that more breakthroughs will be achieved in the future to further optimize the treatment strategies for hematologic malignancies.https://xuebao.shsmu.edu.cn/article/2024/1674-8115/1674-8115-2024-44-12-1607.shtmlantibody-drug conjugate (adc)lymphomaleukemiatargeted therapy |
| spellingShingle | TANG Sijie MI Jianqing Clinical advances in antibody-drug conjugates for hematological malignancies Shanghai Jiaotong Daxue xuebao. Yixue ban antibody-drug conjugate (adc) lymphoma leukemia targeted therapy |
| title | Clinical advances in antibody-drug conjugates for hematological malignancies |
| title_full | Clinical advances in antibody-drug conjugates for hematological malignancies |
| title_fullStr | Clinical advances in antibody-drug conjugates for hematological malignancies |
| title_full_unstemmed | Clinical advances in antibody-drug conjugates for hematological malignancies |
| title_short | Clinical advances in antibody-drug conjugates for hematological malignancies |
| title_sort | clinical advances in antibody drug conjugates for hematological malignancies |
| topic | antibody-drug conjugate (adc) lymphoma leukemia targeted therapy |
| url | https://xuebao.shsmu.edu.cn/article/2024/1674-8115/1674-8115-2024-44-12-1607.shtml |
| work_keys_str_mv | AT tangsijie clinicaladvancesinantibodydrugconjugatesforhematologicalmalignancies AT mijianqing clinicaladvancesinantibodydrugconjugatesforhematologicalmalignancies |